Gary L. Norman

6.5k total citations
123 papers, 4.0k citations indexed

About

Gary L. Norman is a scholar working on Epidemiology, Hepatology and Rheumatology. According to data from OpenAlex, Gary L. Norman has authored 123 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Epidemiology, 51 papers in Hepatology and 41 papers in Rheumatology. Recurrent topics in Gary L. Norman's work include Liver Diseases and Immunity (45 papers), Systemic Lupus Erythematosus Research (38 papers) and Liver Disease Diagnosis and Treatment (31 papers). Gary L. Norman is often cited by papers focused on Liver Diseases and Immunity (45 papers), Systemic Lupus Erythematosus Research (38 papers) and Liver Disease Diagnosis and Treatment (31 papers). Gary L. Norman collaborates with scholars based in United States, Italy and Greece. Gary L. Norman's co-authors include Zakera Shums, Albert J. Czaja, Michael Mähler, Patrick S.C. Leung, M. Eric Gershwin, Walter L. Binder, Pier Luigi Meroni, Munther A. Khamashta, Susan Encabo and Mária Papp and has published in prestigious journals such as Science, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Gary L. Norman

122 papers receiving 3.9k citations

Peers

Countries citing papers authored by Gary L. Norman

Since Specialization

Citations

This map shows the geographic impact of Gary L. Norman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary L. Norman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary L. Norman more than expected).

Fields of papers citing papers by Gary L. Norman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary L. Norman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary L. Norman. The network helps show where Gary L. Norman may publish in the future.

Co-authorship network of co-authors of Gary L. Norman

This figure shows the co-authorship network connecting the top 25 collaborators of Gary L. Norman. A scholar is included among the top collaborators of Gary L. Norman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary L. Norman. Gary L. Norman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Utilizing both IgA tissue transglutaminase and IgG-deamidated gliadin peptide antibodies offers accurate celiac disease diagnosis without duodenal biopsy 2024 ·Digestive and Liver Disease ·Fabiana Zingone, Gary L. Norman, Edgardo Smecuol, Daria Maniero, Antonio Carroccio, Federico Biagi, Juan P. Stefanolo, Sonia I. Niveloni, Geoffrey Holmes, Vincenzo Villanacci, Antonella Santonicola, Julio C. Bai, Carolina Ciacci	2
2	Prevalence of Antiphospholipid Antibodies and Association With Incident Cardiovascular Events 2023 ·JAMA Network Open ·Yu Zuo, Sherwin Navaz, Wenying Liang, Chun Li, Colby Ayers, (unknown), Alyssa Harbaugh, Gary L. Norman, E. Blair Solow, Bonnie L. Bermas, (unknown), Anand Rohatgi, David R. Karp, Jason S. Knight, James A. de Lemos	16
3	KIR/HLA genotypes confer susceptibility and progression in patients with autoimmune hepatitis 2019 ·JHEP Reports ·Takeji Umemura, Satoru Joshita, Hiromi Saito, Kaname Yoshizawa, Gary L. Norman, Eiji Tanaka, Masao Ôta	16
4	The IgA Isotype of Anti-β2 Glycoprotein I Antibodies Recognizes Epitopes in Domains 3, 4, and 5 That Are Located in a Lateral Zone of the Molecule (L-Shaped) 2019 ·Frontiers in Immunology ·Manuel Serrano, José A. Martínez-Flores, Gary L. Norman, Laura Naranjo, José Morales, Antonio Serrano	13
5	Serum Autotaxin Is a Useful Disease Progression Marker in Patients with Primary Biliary Cholangitis 2018 ·Scientific Reports ·Satoru Joshita, Takeji Umemura, Yoko Usami, Yūki Yamashita, Gary L. Norman, Ayumi Sugiura, Tomoo Yamazaki, Naoyuki Fujimori, Takefumi Kimura, Akihiro Matsumoto, Koji Igarashi, Kaname Yoshizawa, Masao Ôta, Eiji Tanaka	27
6	The interplay of type I and type II interferons in murine autoimmune cholangitis as a basis for sex‐biased autoimmunity 2017 ·Hepatology ·Heekyong Bae, Deborah L. Hodge, Guoxiang Yang, Patrick S.C. Leung, Sathi Babu Chodisetti, Julio C. Valencia, Michael Sanford, (unknown), Ziaur S. M. Rahman, Koichi Tsuneyama, Gary L. Norman, M. Eric Gershwin, Howard A. Young	46
7	Genetic Risk Factors for Autoimmune Thyroid Disease might Affect the Susceptibility to and Modulate the Progression of Primary Biliary Cholangitis 2017 ·Journal of Gastrointestinal and Liver Diseases ·Aleksander Kuś, (unknown), Konrad Szymañski, Ewa Wunsch, Małgorzata Milkiewicz, Rafał Płoski, Zakera Shums, Gary L. Norman, Piotr Milkiewicz, Tomasz Bednarczuk, Marcin Krawczyk	8
8	Gut barrier failure biomarkers are associated with poor disease outcome in patients with primary sclerosing cholangitis 2017 ·World Journal of Gastroenterology ·Tamás Tornai, (unknown), Zsuzsanna Vitális, István Tornai, Dávid Tornai, Péter Antal‐Szalmás, Gary L. Norman, Zakera Shums, Gábor Veres, Antal Dezsőfi, Gabriella Pár, Alajos Pár, (unknown), Ferenç Szalay, Péter L. Lakatos, Mária Papp	37
9	Association between serum soluble CD14 and IL‐8 levels and clinical outcome in primary biliary cholangitis 2016 ·Liver International ·Takeji Umemura, (unknown), Satoru Joshita, Tomoo Yamazaki, Naoyuki Fujimori, Soichiro Shibata, Yuki Ichikawa, Michiharu Komatsu, Akihiro Matsumoto, Zakera Shums, Gary L. Norman, Eiji Tanaka, Masao Ôta	18
10	Validity of the global anti-phospholipid syndrome score to predict thrombosis: a prospective multicentre cohort study 2015 ·Lara D. Veeken ·Stéphane Zuily, Bas de Laat, (unknown), Hilde Kelchtermans, Zakera Shums, Roger Albesa, Gary L. Norman, (unknown), Anne‐Christine Rat, J. Ninet, N. Magy‐Bertrand, Jean‐Louis Pasquali, M. Lambert, B. Lorcerie, P. Kaminsky, Françis Guillemin, Véronique Regnault, Denis Wahl	48
11	Anti-Phosphatidylserine-Prothrombin Antibodies are Associated with Outcome in a TIA Cohort 2012 ·Frontiers in Neurology ·Michael T. Mullen, Steven R. Messé, Scott E. Kasner, Lauren Sansing, (unknown), Gary L. Norman, Zakera Shums, Brett Cucchiara	22
12	Autoantibodies to domain 1 of beta 2 glycoprotein 1: A promising candidate biomarker for risk management in antiphospholipid syndrome 2012 ·Autoimmunity Reviews ·Michael Mähler, Gary L. Norman, Pier Luigi Meroni, Munther A. Khamashta	83
13	IgA antibodies against deamidated gliadin peptides in patients with chronic liver diseases 2012 ·Clinica Chimica Acta ·Nikolaos Gatselis, Kalliopi Zachou, Gary L. Norman, (unknown), Matthaios Speletas, Stella Gabeta, Anastasios E. Germenis, George Κ. Koukoulis, George N. Dalekos	12
14	Epithelial cell specificity and apotope recognition by serum autoantibodies in primary biliary cirrhosis 2011 ·Hepatology ·Guanghua Rong, Renqian Zhong, Ana Lleò, Patrick S.C. Leung, Christopher L. Bowlus, Guo–Xiang Yang, (unknown), Ross L. Coppel, Aftab A. Ansari, D Cuebas, Howard J. Worman, Pietro Invernizzi, Gregory J. Gores, Gary L. Norman, Xiao-Song He, Eric M. Gershwin	51
15	Autoimmune acute liver failure: Proposed clinical and histological criteria 2010 ·Hepatology ·R. Todd Stravitz, Jay H. Lefkowitch, Robert J. Fontana, M. Eric Gershwin, Patrick S.C. Leung, Richard K. Sterling, Michael P. Manns, Gary L. Norman, William M. Lee, (unknown)	191
16	IgA Anti-b2GPI Antibodies in Patients with Autoimmune Liver Diseases 2008 ·Journal of Clinical Immunology ·Stella Gabeta, Gary L. Norman, Nikolaos Gatselis, Christos Liaskos, Panagiotis Papamichalis, (unknown), Kalliopi Zachou, Eirini I. Rigopoulou, George N. Dalekos	35
17	Antimitochondrial antibodies in acute liver failure: Implications for primary biliary cirrhosis 2007 ·Hepatology ·Patrick S.C. Leung, Lorenzo Rossaro, Paul A. Davis, Ogyi Park, Atsushi Tanaka, Kentaro Kikuchi, Hiroshi Miyakawa, Gary L. Norman, William M. Lee, Eric M. Gershwin	92
18	Mutations in innate immune receptors modulate the serologic response to microbial antigens in patients with inflammatory bowel disease 2006 ·Gastroenterology ·Liesbet Henckaerts, Marieke Pierik, Karolien Claes, Marc Ferrante, Nele Van Schuerbeek, Nir Dotan, Gary L. Norman, Rom T. Altstock, Iris Dotan, (unknown), (unknown), Paul Rutgeerts, Séverine Vermeire	6
19	Activity of Sera from Patients with Lyme Disease Against Borrelia burgdorferi 1997 ·Clinical Infectious Diseases ·Charles S. Pavia, Gary P. Wormser, Gary L. Norman	16
20	Prevalence of antibodies to human immunodeficiency virus type 1 among blood donors prior to screening, The Transfusion Safety Study/NHLBI Donor Repository 1989 ·Transfusion ·Steven Kleinman, Joyce C. Niland, Stanley P. Azen, Eva A. Operskalski, L. H. Barbosa, Amoz I. Chernoff, Virginia M. Edwards, Bruce A. Lenes, G. June Marshall, George J. Nemo, Gary L. Norman, H. A. Perkins, Johanna Pindyck, Frances A. Pitlick, S Rasheed, K Shriver, Pearl Toy, Peter A. Tomasulo, Alan A. Waldman, J. W. Mosley, (unknown)	31

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact